Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521646

SCHEMBL1521646

SCHEMBL1521646

CNc1ncc2c(n1)N(C(C)C)C(=O)N(c1cc(N)c(F)cc1C)C2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 4/20 0.37
▸ BMX P51813 7/20 0.36
▸ TNK2 Q07912 9/20 0.34
▸ MAP4K2 Q12851 9/20 0.34
▸ FGFR1 P11362 2/20 0.34
▸ FGFR4 P22455 2/20 0.34
▸ FGFR2 P21802 1/20 0.34
▸ LCK P06239 1/20 0.34
▸ FES P07332 1/20 0.34
▸ RET P07949 1/20 0.34
▸ PDGFRB P09619 1/20 0.34
▸ KIT P10721 1/20 0.34
▸ SRC P12931 1/20 0.34
▸ PDGFRA P16234 1/20 0.34
▸ FLT1 P17948 1/20 0.34
▸ FGFR3 P22607 1/20 0.34
▸ EPHA3 P29320 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ EPHB4 P54760 1/20 0.34
▸ TEK Q02763 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521625 0.87 ABL1 (0.47) ABL1BMXTNK2MAP4K2FGFR1
SCHEMBL1521518 0.84 FGFR4 (0.42) ABL1BMXTNK2MAP4K2FGFR1
SCHEMBL1521434 0.83 FGFR4 (0.38) ABL1FGFR1FGFR4FGFR2PDGFRB
SCHEMBL1521414 0.82 FGFR4 (0.41) FGFR1FGFR4FGFR2
SCHEMBL1521500 0.78 RAB9A (0.42) ABL1RETSRCKDREPHB4
SCHEMBL1521598 0.78 BRAF (0.42) ABL1BMXTNK2MAP4K2SRC
SCHEMBL1522022 0.77 ABL1 (0.39) ABL1BMXTNK2MAP4K2SRC
SCHEMBL1521439 0.73 TNK2 (0.47) ABL1BMXTNK2MAP4K2FGFR1
SCHEMBL1521387 0.72 FGFR1 (0.39) ABL1BMXTNK2MAP4K2FGFR1
SCHEMBL1521938 0.71 FGFR4 (0.56) ABL1BMXTNK2MAP4K2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US disclosed
EP-2063896-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 — — EP disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US disclosed
WO-2008033999-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 ABL1 936/4885BMX 947/4885TNK2 119/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 ABL1 936/4885BMX 947/4885TNK2 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.